GlaxoSmithKline (GSK) Has Credit Outlook Cut by Moody's  
7/30/2013 7:18:51 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

The ratings agency said the decision to change its view from stable was due to multi-billion-pound acquisitions, legal settlements over drugs and large share buybacks. Moody’s kept GSK’s A1 rating unchanged, but yesterday’s move raises the chance of a downgrade. While Moody’s “notes the ongoing investigation into GSK by China”, it added that this was “not a trigger for [Monday’s] action”.

Help employers find you! Check out all the jobs and post your resume.